The 2025 Healthcare Organizations Leading SUD Care Honor Roll Results are in!
Between April and June 2025, Cal Hospital Compare (CHC) invited all California adult, acute care hospitals to voluntarily submit their Healthcare Organizations Leading SUD Care Self-Assessment results to be considered for the 2025 Honor Roll. The self-assessment uses 8 questions to measure opioid management across the following four domains of care: 1) safe & effective opioid use, 2) identifying and managing patients with SUD, 3) harm reduction, and 4) applying cross-cutting SUD management best practices.
This year, 133 hospitals participated in the program, and we are proud to recognize their achievements:
- 33 hospitals demonstrated Sustained Improvement
- 17 hospitals achieved Superior Performance
- 33 hospitals were recognized for Excellent Progress
- 32 hospitals were identified as Most Improved
- 42 hospitals were acknowledged for their participation in the 2025 program
Read the full press release here.
To learn more about the 2025 Honor Roll and explore the full list of honorees, view this Fact Sheet. You can learn more about the methodology here.
2025 Program Resources:
- Hospital Self-Assessment_Healthcare Orgs Leading SUD Care_CHC_2025
- Recording: Opioid Care Honor Roll Celebratory Weinbar & 2025 Program Launch
- Slides: Opioid Care Honor Roll Celebratory Webinar & 2025 Program Launch
- Sept 10th Office Hours: Recording & Slide Deck
2024 Program Resources:
- 2024 Fact Sheet – Opioid Care Honor Roll
- Please refer to the 2024 fact sheet for detailed information and to view the list of honor roll recipients.
- 2024 Methodology Primer_Opioid Care Honor Roll
- Opioid Management Hospital Self-Assessment_2024
- Introduction to the 2024 Opioid Care Honor Roll Program Launch Webinar – Aug. 23, 2023
2023 Program Resources:
2021 Program Resources:
Contact Tracy Fisk at tfisk@convergencehealth.org if you need assistance, would like a copy of your hospital’s award certificate or wish to join our mailing distribution list to receive updates.